Related Experiment Video
Updated: May 16, 2026

A BW Reporter System for Studying Receptor-Ligand Interactions
Published on: January 7, 2019
[Clarithromycin therapy of a B cell MALT lymphoma]
L Danilko1, K Haas, U Schönherr
1Augenabteilung, Krankenhauses der Barmherzigen Brüder, Seilerstätte 2, 4020 Linz, Österreich. lukas.danilko@gmx.at
Abstract:
Presentation of a 34-year-old patient with a conjunctival tumor of the left upper circumference of the eyeball clinically presenting as a salmon-pink colored conjunctival tumor. The incisional biopsy and immunohistochemical work-up revealed an extranodal conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma of the marginal zone B cell type. The therapy comprised a currently experimental therapy scheme with 500 mg clarithromycin 3 times per day for 21 days. This therapy achieved a significant tumor regression.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...